Loading...
XNASATYR
Market cap258mUSD
Dec 27, Last price  
3.74USD
1D
-0.80%
1Q
111.30%
Jan 2017
-87.57%
IPO
-98.61%
Name

aTyr Pharma Inc

Chart & Performance

D1W1MN
XNAS:ATYR chart
P/E
—
P/S
731.16
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
90.41%
Rev. gr., 5y
123.39%
Revenues
353k
-96.60%
000000422,00010,455,000010,386,000353,000
Net income
-50m
L+13.80%
-20,014,000-24,350,000-47,973,000-57,855,000-48,207,000-34,515,000-22,237,000-14,958,000-32,464,000-44,277,000-50,389,000
CFO
-33m
L-20.69%
-11,378,000-17,311,000-22,824,000-36,797,000-52,861,000-42,364,000-31,063,000-20,013,000-15,301,000-33,075,000-41,886,000-33,220,999
Earnings
Mar 12, 2025

Profile

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
URL
https://www.atyrpharma.com/
IPO date
May 07, 2015
Employees
65
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
353
-96.60%
10,386
 
Cost of revenue
55,272
58,485
35,319
Unusual Expense (Income)
NOPBT
(54,919)
(48,099)
(35,319)
NOPBT Margin
Operating Taxes
(8)
(1,066)
(1,313)
Tax Rate
NOPAT
(54,911)
(47,033)
(34,006)
Net income
(50,389)
13.80%
(44,277)
36.39%
(32,464)
117.03%
Dividends
Dividend yield
Proceeds from repurchase of equity
66,729
5,517
110,025
BB yield
-88.28%
-8.86%
-77.19%
Debt
Debt current
1,328
894
980
Long-term debt
27,534
22,174
1,776
Deferred revenue
Other long-term liabilities
(1,414)
Net debt
(72,788)
(49,408)
(105,155)
Cash flow
Cash from operating activities
(33,221)
(41,886)
(33,075)
CAPEX
(4,215)
(1,641)
(192)
Cash from investing activities
(20,127)
47,245
(91,566)
Cash from financing activities
66,230
5,451
110,025
FCF
(57,400)
(55,997)
(33,617)
Balance
Cash
98,166
69,311
107,911
Long term investments
3,484
3,165
Excess cash
101,632
71,957
107,911
Stockholders' equity
(468,222)
(418,218)
(372,706)
Invested Capital
573,787
501,036
483,210
ROIC
ROCE
EV
Common stock shares outstanding
53,606
28,420
19,081
Price
1.41
-35.62%
2.19
-70.68%
7.47
92.53%
Market cap
75,585
21.44%
62,239
-56.33%
142,534
301.03%
EV
2,609
12,651
37,204
EBITDA
(52,178)
(46,404)
(34,015)
EV/EBITDA
Interest
1,695
Interest/NOPBT